Aurinia Submits IND Application to US Food & Drug Administration for AUR 200
AUR200, a potent recombinant fusion protein, has a clinically validated MOA with a high affinity for targeting both BAFF and APRIL Upon FDA clearance of the IND, AUR 200 will be studied in a...
United States Volker Knappertz Research Development Drug Administration American College Of Rheumatology Convergence Aurinia Pharmaceuticals
Source: marketscreener.com